Novel microbial biomarkers for predicting risk of colorectal cancer or colorectal adenoma
By using specific oligonucleotide primers and polynucleotide probes combined with PCR technology in the kit, the DNA or RNA of Christensenella hongkongensis was quantitatively detected, which solved the problem of early diagnosis of CRC and colorectal adenomas and improved the early recognition of the disease and predictive ability, improving patient outcomes.
Patent Information
- Application Number
- CN202310257771.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-06
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-03-06
AI Technical Summary
The existing diagnostic methods for colorectal cancer (CRC) and colorectal adenomas have difficulty in early detection, resulting in low patient survival rates, and it is difficult for the prior art to effectively identify specific microbial markers associated with these diseases.
A kit was developed to detect fecal samples by specifically and quantitatively identifying the DNA or RNA of Christensenella hongkongensis using oligonucleotide primers, polynucleotide probes and RT-PCR, real-time quantitative PCR or metagenic sequencing technology. Christensenella hongkongensis abundance in the diagnosis of CRC and colorectal adenomas.
It improves the accuracy of early diagnosis of CRC and colorectal adenomas, enhances the predictive ability of patient risks, and improves disease prognosis.
Smart Images

Figure CN116377070B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the identification of bacterial species that help improve the diagnosis of colorectal adenomas and the development of new bacterial markers for the diagnosis of CRC. In particular, the present application relates to the specific and quantitative identification of DNA or RNA that is unique to Christensenella hongkongensis (NCBI: txid270498; old name: Catabacter hongkongensis). Background Art
[0002] Colorectal cancer (CRC) is one of the most common malignancies worldwide and one of the most deadly cancers. However, early diagnosis and treatment can greatly improve the survival rate of colorectal cancer patients. Early detection of CRC can promote successful treatment, prevention and reduce the incidence of CRC. In fact, the survival rate of patients with stage I colorectal cancer can reach more than 95%. There are a large number of microorganisms in the human intestine. Recent evidence shows that changes in these intestinal microbial environments are associated with the occurrence of colorectal tumors. Abnormal intestinal flora composition is considered to be a potential important cause of the occurrence and development of CRC. 1 . As metagenomic sequencing technology matures, more new bacteria have been identified, some of which are closely related to CRC and colorectal adenoma. These bacteria have the potential to be developed into specific microbial markers for predicting the risk of CRC and colorectal adenoma. By detecting the abundance of these bacteria, a diagnosis and risk prediction model for CRC and colorectal adenoma can be established, which will help to detect and diagnose CRC and colorectal adenoma as early as possible and improve the prognosis of CRC and colorectal adenoma. Summary of the invention
[0003] In a first aspect, the present application provides a kit for detecting colorectal cancer or colorectal adenoma in a subject, comprising: a reagent that specifically and quantitatively identifies DNA or RNA that is unique to Christensenella hongkongensis.
[0004] In some embodiments, the DNA or RNA specific to Christensenella hongkongensis comprises the nucleic acid sequence shown in SEQ ID NO:1.
[0005] In some embodiments, the reagents for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprise oligonucleotide primers comprising the nucleic acid sequences shown in SEQ ID NO:2 and SEQ ID NO:3.
[0006] In some embodiments, the reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprises the polynucleotide probe set forth in SEQ ID NO:4.
[0007] In some embodiments, the kit further comprises a standard control that provides an average amount of Christensenella hongkongensis in a stool sample.
[0008] In some embodiments, the reagent comprises a detectable moiety.
[0009] In some embodiments, the kit further comprises an operating manual.
[0010] In a second aspect, the present application provides use of a reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis in preparing a kit for detecting colorectal cancer or colorectal adenoma in a subject.
[0011] In some embodiments, the DNA or RNA specific to Christensenella hongkongensis comprises the nucleic acid sequence shown in SEQ ID NO:1.
[0012] In some embodiments, the reagents for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprise oligonucleotide primers comprising the nucleic acid sequences shown in SEQ ID NO:2 and SEQ ID NO:3.
[0013] In some embodiments, the reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprises the polynucleotide probe set forth in SEQ ID NO:4.
[0014] In some embodiments, the kit further comprises a standard control that provides an average amount of Christensenella hongkongensis in a stool sample.
[0015] In some embodiments, the reagent comprises a detectable moiety.
[0016] In some embodiments, the reagent quantitatively identifies the DNA or RNA by RT-PCR, real-time quantitative PCR, or metagenomic sequencing.
[0017] As non-limiting examples, the present application provides the following embodiments:
[0018] Embodiment 1. A kit for detecting colorectal cancer or colorectal adenoma in a subject, comprising: a reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis.
[0019] Embodiment 2. The kit according to embodiment 1, wherein
[0020] The DNA or RNA specific to Christensenella hongkongensis comprises the nucleic acid sequence shown in SEQ ID NO:1.
[0021] Embodiment 3. The kit of embodiment 1, wherein the reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprises oligonucleotide primers, wherein the oligonucleotide primers comprise nucleic acid sequences shown in SEQ ID NO: 2 and SEQ ID NO: 3; or
[0022] The reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprises a polynucleotide probe represented by SEQ ID NO:4.
[0023] Embodiment 4. The kit of embodiment 1, further comprising a standard control providing an average amount of Christensenella hongkongensis in a stool sample.
[0024] Embodiment 5. The kit of embodiment 1, wherein the reagent comprises a detectable portion.
[0025] Embodiment 6. The kit as described in embodiment 1 further comprises an operation manual.
[0026] Embodiment 7. Use of an agent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis in the preparation of a kit for detecting colorectal cancer or colorectal adenoma in a subject.
[0027] Embodiment 8. The use according to embodiment 7, wherein
[0028] The DNA or RNA specific to Christensenella hongkongensis comprises the nucleic acid sequence shown in SEQ ID NO:1.
[0029] Embodiment 9. The use according to embodiment 7, wherein the reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprises an oligonucleotide primer comprising a nucleic acid sequence shown in SEQ ID NO: 2 and SEQ ID NO: 3; or
[0030] The reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprises a polynucleotide probe represented by SEQ ID NO:4.
[0031] Embodiment 10. The use according to embodiment 7, wherein the kit further comprises a standard control, which provides the average amount of Christensenella hongkongensis in the stool sample.
[0032] Embodiment 11. The use according to embodiment 7, wherein the agent comprises a detectable portion.
[0033] Embodiment 12. The use according to embodiment 7, wherein
[0034] The reagent is used to quantitatively identify the DNA or RNA by RT-PCR, real-time quantitative PCR or metagenomic sequencing. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 : Fecal levels of Christensenella hongkongensis in CRC patients, colorectal adenoma patients, and control subjects assessed by qPCR, where N indicates normal control; CRC indicates colorectal cancer; and A indicates colorectal adenoma.
[0036] Figure 2 : ROC curve analysis of the performance of Christensenella hongkongensis in CRC. Where N represents normal control; CRC represents colorectal cancer. AUC represents the area under the receiver operating characteristic curve.
[0037] Figure 3 :ROC curve analysis of the performance of Christensenella hongkongensis in colorectal adenoma. Where N represents normal control; A represents colorectal adenoma. AUC represents the area under the receiver operating characteristic curve.
[0038] Sequence Description
[0039] SEQ ID NO:1 to SEQ ID NO:4 are respectively a gene marker for Christensenella hongkongensis (SEQ ID NO:1), a forward primer (Chk-F, SEQ ID NO:2) and a reverse primer (Chk-R, SEQ ID NO:3) for detecting the gene marker, and a probe for detecting the gene marker (Chk-probe, SEQ ID NO:4).
[0040] SEQ ID NO: 5 to SEQ ID NO: 7 are respectively a forward primer (CF, SEQ ID NO: 5) and a reverse primer (CR, SEQ ID NO: 6) for detecting the internal reference 16S, and a probe (C-probe, SEQ ID NO: 7) for detecting the internal reference 16S.
[0041] definition
[0042] In this application, the terms "colorectal cancer (CRC)", "large bowel cancer" and "intestinal cancer" have the same meaning and refer to cancer of the large intestine (colon), the lower part of the human digestive system. "Colorectal cancer cells" are colorectal epithelial cells that have characteristics of colorectal cancer, and include precancerous cells, i.e., cells that are in the early stages of transformation into cancer cells or are prone to transformation into cancer cells. Such cells may exhibit one or more phenotypic traits characteristic of cancerous cells.
[0043] In this disclosure, the term "or" is generally used in its sense including "and / or" unless explicitly stated otherwise.
[0044] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single-stranded or double-stranded form. Unless otherwise specified, the term encompasses nucleic acids including known analogs of natural nucleotides that have similar binding properties to reference nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a specific nucleic acid sequence also implicitly encompasses variants (e.g., degenerate codon substitutions), alleles, orthologs, single nucleotide polymorphisms (SNPs) and complementary sequences thereof and sequences explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating a sequence in which the third position of one or more selected (or all) codons is replaced by mixed bases and / or deoxyinosine residues. The term nucleic acid can be used interchangeably with genes, cDNAs, and mRNAs encoded by genes.
[0045] The term "gene" refers to a DNA segment involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) that are involved in the transcription / translation of the gene product and the regulation of transcription / translation, as well as intervening sequences (introns) between individual coding segments (exons).
[0046] As used herein, "primer" refers to an oligonucleotide that can be used in an amplification method (such as polymerase chain reaction (PCR)) to amplify a nucleotide sequence based on a polynucleotide sequence corresponding to a target gene (e.g., a DNA or RNA sequence of a related bacterial species). Typically, at least one PCR primer for amplifying a polynucleotide sequence is sequence-specific for the polynucleotide sequence. The exact length of a primer depends on multiple factors, including temperature, primer source, and the method used. For example, for diagnosis and prognosis applications, depending on the complexity of the target sequence, an oligonucleotide primer typically contains at least 10, at least 15, at least 20, or at least 25 or more nucleotides, although it may contain fewer nucleotides or more nucleotides. The factors involved in determining the appropriate length of a primer are well known to those skilled in the art.
[0047] A "label," "detectable marker," or "detectable moiety" is a moiety that can be detected by spectrophotometric, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include 32 P, fluorescent dyes, electron-dense reagents, enzymes (e.g., enzymes commonly used in ELISA), biotin, digoxigenin, or haptens and proteins that can be made detectable (e.g., by incorporating a radioactive component into the peptide) or used to detect antibodies that react specifically with the peptide. Typically, the detectable label is linked to a probe or molecule with defined binding properties (e.g., a polypeptide or polynucleotide with known binding specificity) to allow easy detection of the presence of the probe (and its bound target).
[0048] As used herein, "standard control" refers to a polynucleotide sequence or polypeptide (e.g., DNA, RNA or protein of related bacteria) present in an established disease-free stool sample (e.g., stool samples from average healthy individuals who have not been diagnosed with CRC or are known to have an increased risk of developing into CRC). Standard control values are suitable for the inventive method as the basis for the amount of DNA, RNA or protein of related bacteria present in the comparative test sample. As a standard control, an average amount of DNA, RNA or protein of related bacteria common in stool samples of average healthy people who do not suffer from any conventionally defined colon disease (especially CRC) is provided. Standard control values can vary according to the properties of the sample and other factors, such as the sex, age, race of the individual as the basis for establishing the control value.
[0049] When used to describe healthy people who do not suffer from any colorectal disease (especially CRC) of conventional definition, the term "average" refers to certain characteristics in human fecal samples of healthy people who do not suffer from any colorectal disease (especially CRC) and do not have the known risk of developing into the disease that can represent random selection, especially the level of DNA, RNA or protein of some related bacteria. The selected crowd should include a sufficient number of people so that the average level or amount of the DNA, RNA or protein of the related bacteria found in the feces of these individuals can reflect the corresponding level or amount of these DNA, RNA or protein in general healthy people with reasonable accuracy. In addition, the selected crowd is usually used to test the object of colorectal cancer indication with fecal sample and has a similar age. In addition, other factors such as sex, race, medical history should also be considered, and preferably the test subject is closely matched with the selected individual group of the establishment "average" value in the feature.
[0050] As used in this application, the term "amount" refers to the amount of a polynucleotide or polypeptide of interest (e.g., DNA, RNA or protein of a related bacterium) present in a sample. Such an amount can be expressed as an absolute value, i.e., the total amount of the polynucleotide or polypeptide in the sample, or as a relative value, i.e., the concentration of the polynucleotide or polypeptide in the sample.
[0051] In this application, Christensenella hongkongensis may also be abbreviated as Chk. DETAILED DESCRIPTION
[0052] In a first aspect, the present application provides a kit for detecting colorectal cancer or colorectal adenoma in a subject, comprising: a reagent that specifically and quantitatively identifies DNA or RNA that is unique to Christensenella hongkongensis.
[0053] In some embodiments, the reagents specifically and quantitatively identify DNA or RNA unique to Christensenella hongkongensis.
[0054] In some embodiments, the DNA or RNA specific to Christensenella hongkongensis comprises the nucleic acid sequence shown in SEQ ID NO:1.
[0055] In some embodiments, the reagents comprise a set of two oligonucleotide primers, wherein the set of two oligonucleotide primers comprises the nucleic acid sequences shown in SEQ ID NO:2 and SEQ ID NO:3.
[0056] In some embodiments, the reagent comprises a polynucleotide probe shown in SEQ ID NO:4.
[0057] In some embodiments, the kit further comprises a standard control that provides an average amount of Christensenella hongkongensis in a stool sample.
[0058] In some embodiments, the kit includes reagents for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis; optionally, the kit is used to detect colorectal cancer and / or colorectal adenoma in a subject, preferably, the adenoma is a non-advanced adenoma or an advanced adenoma.
[0059] In some embodiments, the reagent comprises a detectable moiety.
[0060] In some embodiments, the reagent for specifically and quantitatively identifying the unique DNA or RNA of the target bacteria generally includes at least one oligonucleotide that can be used for specific hybridization with at least one segment of the target DNA or RNA sequence or its complementary sequence. In some embodiments, this oligonucleotide is labeled with a detectable portion. In some embodiments, the reagent may include at least two oligonucleotide primers that can be used for at least one segment of the target bacteria DNA or RNA amplification by PCR (including by RT-PCR). In some embodiments, the reagent may include at least one oligonucleotide probe that can be used for binding at least one segment of the target bacteria DNA or RNA. In some embodiments, a detectable portion of a labeled primer or probe is used.
[0061] In some embodiments, using 3 H. 125 I. 35 S. 14 C or 32 In some embodiments, the probe or primer is directly conjugated to a label such as a fluorophore, a chemiluminescent agent, and an enzyme. The choice of the detectable moiety depends on the sensitivity required, the convenience of conjugation to the probe or primer, the stability requirements, and the available instruments.
[0062] In some embodiments, the probe carries a 5' reporter dye FAM (6-carboxyfluorescein) or VIC (4,7,2'-trichloro-7'-phenyl-6-carboxyfluorescein) and a 3' quencher dye TAMRA (6-carboxytetramethyl-rhodamine).
[0063] In some embodiments, the kit further comprises an operating manual.
[0064] In a second aspect, the present application provides use of a reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis in preparing a kit for detecting colorectal cancer or colorectal adenoma in a subject.
[0065] In some embodiments, the DNA or RNA specific to Christensenella hongkongensis comprises the nucleic acid sequence shown in SEQ ID NO:1.
[0066] In some embodiments, the reagents for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprise oligonucleotide primers comprising the nucleic acid sequences shown in SEQ ID NO:2 and SEQ ID NO:3.
[0067] In some embodiments, the reagent for specifically and quantitatively identifying DNA or RNA unique to Christensenella hongkongensis comprises the polynucleotide probe set forth in SEQ ID NO:4.
[0068] In some embodiments, the kit further comprises a standard control that provides an average amount of Christensenella hongkongensis in a stool sample.
[0069] In some embodiments, the reagent comprises a detectable moiety.
[0070] In some embodiments, the reagent quantitatively identifies the DNA or RNA by RT-PCR, real-time quantitative PCR, or metagenomic sequencing.
[0071] In some embodiments, the reagent can also quantitatively identify the DNA or RNA by at least one method selected from the following: in situ hybridization, polymerase chain reaction (PCR), RNase protection assay (RPA), northern blot, microarray and high-throughput sequencing.
[0072] In some embodiments, the nucleic acid sequence shown in SEQ ID NO: 1 is quantitatively identified by RT-PCR, real-time quantitative PCR, or metagenomic sequencing.
[0073] In some embodiments, colorectal cancer or colorectal adenoma is diagnosed by comparing the level of the DNA or RNA to a standard control.
[0074] In a third aspect, the present application provides a method for assessing the risk of colorectal cancer or colorectal adenoma in a subject, comprising the following steps:
[0075] (a) quantitatively determining the level of Christensenella hongkongensis in a stool sample taken from the subject;
[0076] (b) comparing the level obtained in step (a) with a standard control;
[0077] (c) determining the level obtained in step (a) as an increase or decrease relative to a standard control; and
[0078] (d) identifying the subject as having an increased risk of colorectal cancer or colorectal adenoma.
[0079] In some embodiments, step (a) comprises determining the level of DNA or RNA specific to Christensenella hongkongensis.
[0080] In some embodiments, step (a) comprises determining the level of DNA specific to Christensenella hongkongensis.
[0081] In some embodiments, when the subject is determined to have an increased risk of colorectal cancer or colorectal adenoma, further comprising repeating step (a) at a subsequent time using another stool sample from the subject at a subsequent time.
[0082] In a fourth aspect, the present application provides a method for detecting an increase or decrease in the level of Christensenella hongkongensis in a stool sample, comprising the following steps:
[0083] (a) Quantitative determination of the level of Christensenella hongkongensis in fecal samples;
[0084] (b) comparing the level obtained in step (a) with a standard control;
[0085] (c) determining the level obtained in step (a) as an increase or decrease relative to a standard control.
[0086] In some embodiments, the stool sample is obtained from a human subject.
[0087] In some embodiments, step (a) comprises determining the level of DNA or RNA specific to Christensenella hongkongensis.
[0088] In some embodiments, step (a) comprises determining the level of DNA specific to Christensenella hongkongensis.
[0089] Example
[0090] The following examples are provided for illustration only and are not limiting. Those skilled in the art will readily recognize that a variety of noncritical parameters can be changed or modified to produce essentially the same or similar results.
[0091] Example 1
[0092] Analysis of the bacterial microbiome
[0093] This study integrated the public stool metagenomic data of 335 cases (177 CRC patients and 158 controls) from colorectal cancer (CRC) cohorts in 4 countries / regions around the world (Japan, Austria, France, and Germany), and analyzed the stool metagenomic sequencing data of a study cohort of 1067 cases (174 CRC patients and 893 controls) from Hong Kong, China. 2 Profiling of bacterial community composition was performed on metagenomic trimmed reads. 2 The mapped reads and annotation of species pan-genomes to clade-specific marker genes were completed. The output table contained bacterial species at different levels and their relative abundance.
[0094] Statistical analysis
[0095] Significantly different bacterial taxa between CRC and controls were identified by multivariate association linear model (MaAsLin, website: huttenhower.sph.harvard.edu / galaxy / ).The performance of bacterial species in predicting CRC was evaluated by Lasso (least absolute shrinkage and selection operator) analysis.
[0096] result
[0097] The results showed that the relative abundance of Christensenella hongkongensis (Chk) was positively correlated with CRC in both the global integrated data and the Hong Kong, China data (Table 1).
[0098] Table 1 Results of multivariate linear model analysis
[0099]
[0100] A pval<0.05 was considered statistically significant.
[0101] Example 2
[0102] Human stool sample collection
[0103] Fecal samples were collected from 411 subjects (106 CRC patients, 190 colorectal adenoma patients, and 115 normal controls).
[0104] The inclusion criteria for CRC patients in the collection subjects were: 1) 40-75 years old, 2) asymptomatic individuals or individuals showing the following symptoms, such as changes in bowel habits, rectal bleeding, abdominal pain or anemia, 3) will undergo colonoscopy, 4) samples were collected before or one month after colonoscopy and before resection of the cancer, 5) pathological histology confirmed cancer; Exclusion criteria were: 1) patients in the active stage of inflammatory bowel disease; 2) patients had taken antibiotics in the past month.
[0105] The inclusion criteria for patients with colorectal adenoma in the collection subjects were: 1) 40-75 years old, 2) asymptomatic individuals or individuals showing the following symptoms, such as changes in bowel habits, rectal bleeding, abdominal pain or anemia, 3) those who would undergo colonoscopy, 4) samples were collected before or one month after colonoscopy and before adenoma removal, 5) pathological histology confirmed the diagnosis of adenoma; Exclusion criteria were: 1) patients in the active stage of inflammatory bowel disease; 2) patients who had taken antibiotics in the past month.
[0106] The inclusion criteria for normal controls among the collected subjects were: 1) 40-75 years old, 2) asymptomatic individuals or individuals showing the following symptoms, such as changes in bowel habits, rectal bleeding, abdominal pain or anemia, 3) will undergo colonoscopy, 4) samples were collected before or one month after colonoscopy, 5) normal colonoscopy; Exclusion criteria were: 1) patients in the active stage of inflammatory bowel disease; 2) patients who had taken antibiotics in the last month.
[0107] Subjects collected stool samples in standardized containers. Samples were stored in a −20°C freezer immediately upon arrival at the laboratory and subsequently stored at −80°C until further analysis. Patients with CRC or colorectal adenoma were diagnosed by colonoscopy and histopathological examination of any biopsies.
[0108] DNA extraction
[0109] (1) Place the stool samples collected from the subjects on ice before the experiment;
[0110] (2) Transfer about 100 mg of fecal sample to a grinding tube (containing glass beads).
[0111] (3) Add 700 μl of resuspension solution, 70 μl of lysis enhancement solution and 20 μl of proteinase K to the sample and vortex at the maximum speed of the vortex machine or transfer to an oscillating disruptor.
[0112] (4) Grind the sample at high speed for about 10 minutes
[0113] (5) Transfer to a water bath or metal bath and incubate at 70°C for 20 min to further lyse the sample.
[0114] (6) Centrifuge at 13,000 × g for 5 minutes.
[0115] (7) Transfer 540 μl of supernatant to a new 2.0 ml centrifuge tube, add 180 μl of precipitate, vortex for 30 seconds, place in a 4°C refrigerator or on ice for 10 minutes, and centrifuge at 13,000 × g for 5 minutes.
[0116] (8) Pipette 500 μl of supernatant into a new 1.5 ml centrifuge tube and add 500 μl of lysis and binding buffer.
[0117] 20 μl magnetic beads, vortex at high speed for 30 seconds, let stand at room temperature for 5 to 10 minutes for nucleic acid adsorption, vortex several times during the standing period.
[0118] (9) Transfer to a magnetic rack for magnetic separation and discard the solution by pouring or aspirating it. (Magnetic separation operation suggestions: After placing the centrifuge tube on the magnetic rack, gently turn it left and right. After the magnetic beads gather on the tube wall close to the magnetic rack, gently invert the magnetic rack 2 to 3 times to allow the magnetic beads on the tube cap to also gather on the tube wall. Let it stand for 2 minutes until the magnetic beads are completely adsorbed to the wall).
[0119] (10) Add 800 μl of washing solution 1, vortex for 10 seconds, and perform magnetic separation until the solution is clear. Discard the solution by decantation or aspiration.
[0120] (11) Add 800 μl of washing solution 2, vortex for 10 seconds, and perform magnetic separation until the solution is clear. Discard the solution by decantation or aspiration.
[0121] (12) Add 800 μl of Wash Buffer 2 again, vortex for 10 seconds, and perform magnetic separation until the solution is clear. Discard the solution by decantation or aspiration.
[0122] (13) Discard all solution thoroughly, open the tube cap, and air dry for 3 to 5 minutes.
[0123] (14) Add 100 μl of elution buffer and vortex at high speed for 2 to 3 minutes to break up the magnetic beads.
[0124] (15) Incubate at 60°C for 6 min, then vortex at high speed for 30 sec and transfer to a magnetic rack for magnetic separation.
[0125] (16) Transfer the supernatant nucleic acid to a new centrifuge tube for later use.
[0126] Primer and probe design and qPCR experiments
[0127] In this study, primers and probe sequences specifically for Christensenella hongkongensis were designed (Table 2). In brief, according to conventional methods, the specific gene sequence of Chk was first downloaded from the MetaPhlAn database, and the specificity of Chk was identified using the BLAST program using public databases (such as GenBank). Then, Primer3Plus (https: / / www.primer3plus.com / index.html) was used to design primers and probes, and the Tm value, GC content, and possible secondary structure were determined. The primer and probe sequences for the 16s rDNA internal control were the same as those reported in previous studies. 3,4 . The Chk probe carries a 5' reporter dye FAM (6-carboxyfluorescein) and a 3' quencher dye TAMRA (6-carboxytetramethylrhodamine). The 16S probe carries a 5' reporter dye VIC (4,7,2'-trichloro-7'-phenyl-6-carboxyfluorescein) and a 3' quencher dye TAMRA (6-carboxytetramethylrhodamine). Primers and hydrolysis probes were synthesized by BGI Bio-Solutions HongKong Co., Limited. PCR amplification specificity was confirmed by direct Sanger sequencing of PCR products or by sequencing randomly selected TA clones. The relative abundance of each marker gene was calculated using the delta Cq method by comparing with the internal control abundance and displayed as a logarithmic value of "*10e6+1".
[0128] Table 2. Nucleotide sequences of primers and probes used in this study
[0129]
[0130] Statistical analysis
[0131] The values were expressed as mean ± SD or median (interquartile range (IQR)), as appropriate. The differences in bacterial abundance were determined by the Mann-Whitney U test. The diagnostic value of Chk in distinguishing CRC patients from colorectal adenoma patients was evaluated by receiver operating characteristic (ROC) curve. 5 The critical value is determined by maximizing the Youden index (J = Sensitivity + Specificity - 1) on the receiver operating characteristic (ROC) curve.5 All tests were performed with Graphpad Prism 5.0 (Graphpad Software Inc., San Diego, CA) or MedCalc Statistical Software V.18.5 (MedCalc Software bvba, Ostend, Belgium; website: medcalc.org; 2018). P < 0.05 was considered statistically significant.
[0132] result
[0133] Diagnostic performance of Christensenella hongkongensis in stool for CRC
[0134] By targeted quantitative assessment using qPCR, Christensenella hongkongensis levels were significantly higher in CRC patients compared with control subjects (p = 0.0384, Mann-Whitney rank sum test, Figure 1 ). Receiver operating characteristic (ROC) analysis showed that the AUC of Christensenella hongkongensis for CRC was 0.5689 (95% CI: 0.4931 to 0.6447; P = 0.0769, Figure 2 The critical value determined by maximizing Youden index (J = Sensitivity + Specificity - 1) was 1.659, and the sensitivity and specificity were 31.1% and 81.7%, respectively.
[0135] Diagnostic performance of Christensenella hongkongensis in stool for colorectal adenomas
[0136] By targeted quantitative assessment using qPCR, Christensenella hongkongensis levels were significantly higher in patients with colorectal adenomas compared with control subjects (p = 0.0010, Mann-Whitney rank sum test, Figure 1 ). Receiver operating characteristic (ROC) analysis showed that the AUC of Christensenella hongkongensis for colorectal adenoma was 0.6009 (95% CI: 0.5360 to 0.6659; P = 0.0031, Figure 3 The critical value determined by maximizing Youden index (J = Sensitivity + Specificity - 1) was 0.1343, and the sensitivity and specificity were 50.0% and 70.4%, respectively.
[0137] In summary, the present application selected a suitable bacterial marker Chk and designed qPCR probes and primers for the specific gene fragment sequence of Chk. By using targeted quantification of qPCR to measure the abundance of Chk in feces, it can assist in the diagnosis of CRC and colorectal adenoma, thereby improving the prognosis of CRC and colorectal adenoma.
[0138] References
[0139] 1. Irrazabal, T., Belcheva, A., Girardin, SE, Martin, A. & Philpott, DJ. The multifaceted role of the intestinal microbiota in colon cancer. Molecular cell 54, 309-320 (2014).
[0140] 2. Beghini, F., et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. Elife 10 (2021).
[0141] 3.Liang,Q.,et al.Fecal Bacteria Act as Novel Biomarkers forNoninvasive Diagnosis of Colorectal Cancer.Clin Cancer Res 23,2061-2070(2017).
[0142] 4.Liang,JQ,et al.Anovel faecal Lachnoclostridium marker for thenon-invasive diagnosis of colorectal adenoma and cancer.Gut 69,1248-1257(2020).
[0143] 5.Youden,WJIndex for rating diagnostic tests.Cancer 3,32-35(1950).
[0144] Sequence Listing
[0145] SEQ ID NO:1-Chk gene marker (fragment)
[0146] Region 77834 to 77920 of the whole genome shotgun sequence of Christensenella hongkongensis (Catabacter hongkongensi) strain DSM 18959Ga0310494_103 (GenBank: SMCZ01000003.1)
[0147] (Region from 77834 to 77920 of Christensenella hongkongensis(Catabacter hongkongensi)strain DSM 18959Ga0310494_103,whole genome shotgun sequence(GenBank:SMCZ01000003.1))
[0148] GGGGCTTGAATCCGTTCTTATGCGTTCTGATCGGCCTTGCAGCCGGCGCGTTCGTCGGGTTCATCAATGGACTTTTGGTTGCAAAGC
[0149] SEQ ID NO:2-Chk-F
[0150] GGGGCTTGAATCCGTTCTTA
[0151] SEQ ID NO:3-Chk-R
[0152] GCTTTGCAACCAAAAGTCCA
[0153] SEQ ID NO:4-Chk-probe
[0154] CCTTGCAGCCGGCGCGTTCGT
[0155] SEQ ID NO:5-CF
[0156] CGTCAGCTCGTGYCGTGAG
[0157] SEQ ID NO:6-CR
[0158] CGTCRTCCCCRCCTTCC
[0159] SEQ ID NO:7-C-probe
[0160] TTAAGTCCCRYAACGAGCGCAACCC.
Claims
1. Use of a reagent for specifically and quantitatively identifying DNA unique to Christensenella hongkongensis in the preparation of a kit for detecting colorectal cancer or colorectal adenoma in a subject, in, The DNA specific to Christensenella hongkongensis comprises the nucleic acid sequence shown in SEQ ID NO: 1; The reagent for specifically and quantitatively identifying DNA unique to Christensenella hongkongensis comprises an oligonucleotide primer pair consisting of a first primer having a nucleic acid sequence as shown in SEQ ID NO:2 and a second primer having a nucleic acid sequence as shown in SEQ ID NO:
3.
2. The use according to claim 1, wherein the reagent for specifically and quantitatively identifying DNA unique to Christensenella hongkongensis further comprises a polynucleotide probe as shown in SEQ ID NO:
4.
3. The use according to claim 1 or 2, wherein the kit further comprises a standard control, which provides the average amount of Christensenella hongkongensis in a stool sample.
4. The use of claim 1, wherein the oligonucleotide primer pair comprises a detectable portion.
5. The use of claim 2, wherein the polynucleotide probe comprises a detectable portion.
6. The use according to claim 1 or 2, in, The reagent quantitatively identifies the DNA by reverse transcription PCR, real-time quantitative PCR or metagenomic sequencing.
